RUNX1 and acute lymphoblastic leukemia: In conclusion, our results suggested that only B-ALL patients with a favorable genotype (ETV6-RUNX1 positivity or hyperdiploidy) who achieved an early negative MRD status (10–4) were suitable candidates for dosage reduction of daunorubicin during the induction remission.